Seeking Alpha
 

Johnson & Johnson (JNJ)

- NYSE
  • Apr. 11, 2012, 11:10 AM
    The judge in an Arkansas case against Johnson & Johnson (JNJ -0.5%) tags the firm with a $1.1B penalty after it was found guilty of deception over the marketing of antipyschotic drug Risperdal. Shares of JNJ are snoozing the news with the verdict and obligatory appeal already anticipated.
    | 4 Comments
  • Apr. 11, 2012, 8:57 AM
    Johnson & Johnson (JNJ) could face a massive fine after an Arkansas jury yesterday found the company and its Janssen unit guilty of engaging in "false or deceptive acts" about the risks of the antipsychotic drug Risperdal, and of breaking consumer laws. It's not the first case J&J has lost over Risperdal. Arkansas is seeking $1.25B in fines. (previous)
    | Comment!
  • Apr. 4, 2012, 2:48 PM
    General Mills (GIS) is the most reputable company in America, according to a study (.pdf) of U.S. consumers conducted by the Reputation Institute. General Mills unseated former top finisher Amazon (AMZN), which fell to #5. KFT, JNJ, and K round out the top 5. AIG and XOM saw major improvements in reputation, while TWC and BAC saw major declines.
    | 2 Comments
  • Apr. 4, 2012, 10:02 AM
    FDA approval for the expanded use of Johnson & Johnson's (JNJ -0.5%) Intelence antiretroviral drug will improve the company's position in the evolving anti-infectives market. The approval provides JNJ with a drug that caters to the needs of young children and adolescents suffering from HIV.
    | Comment!
  • Mar. 26, 2012, 10:05 AM
    Johnson & Johnson (JNJ) plans to seek FDA approval in Q2 to use its Xarelto treatment for preventing lung clots after a large-scale Phase III study showed that the drug is as effective as and safer than standard treatments, which include Warfarin. Lung clots affect 600K Americans a year and kill up to 100K. (PR)
    | 2 Comments
  • Mar. 21, 2012, 3:34 PM
    Johnson & Johnson (JNJ -0.1%) and GlaxoSmithKline (GSK -0.2%) join forces with VC firm Index Ventures to form a €150M ($199M) life sciences fund to identify and invest in early stage technologies in disease areas with high market needs.
    | Comment!
  • Mar. 21, 2012, 6:33 AM
    Johnson & Johnson's (JNJ) defense against 550 lawsuits over a vaginal mesh implant could get more complicated after Bloomberg reveals that the company sold the device for two years without the FDA being aware of it, and three years before it was approved.
    | 2 Comments
  • Mar. 15, 2012, 10:56 AM
    Johnson & Johnson's (JNJ) William Weldon has been ripped as one of America's most-overpaid big company CEOs, and it looks like the coin will continue even on his way out the door: Weldon stands to collect pension benefits and deferred compensation valued at $143.5M after his retirement.
    | 9 Comments
  • Mar. 12, 2012, 1:15 PM
    Johnson & Johnson (JNJ +0.4%) faces pressure from the U.S. government to up its offer to settle a long-standong civil investigation probe into the marketing practices of the company over its antipsychotic treatment Risperdal, according to sources. The latest figure of $1.8B offered by the DOJ is considerably higher than the rejected $1B offer previously negotiated out by the U.S. Attorney's office in Philadelphia.
    | 1 Comment
  • Mar. 8, 2012, 9:57 AM
    More on Johnson & Johnson's (JNJ +1.3%) Zytiga success: The company expects to file for FDA approval in the second half of 2012 for the prostate cancer treatment. Shares of rival Dendreon (DNDN -16.3%) react negatively to the development, while Medivation (MDVN +9.2%) soars because it's developing a prostate cancer drug that is a close version of Zytiga.
    | 1 Comment
  • Mar. 8, 2012, 8:47 AM
    Word that a Zytiga phase 3 prostate cancer trial conducted by a unit of Johnson & Johnson (JNJ) was stopped early positive for efficacy creates a ripple effect with companies involved in developing prostate cancer drugs. Premarket movers: JNJ +0.7%, DNDN -15.1%, MDVN +4.4%.
    | Comment!
  • Feb. 29, 2012, 10:17 AM
    Morningstar's Ultimate Stock Pickers offer their 10 highest conviction buys: GILD, GSK, RIMM, C, DVN, ITW, SCHW, JNJ, TIF, DHR.
    | Comment!
  • Feb. 22, 2012, 8:48 AM
    Johnson & Johnson (JNJ) has submitted concessions in a bid to ease EU regulatory concerns over its $21.3B purchase of Swiss medical device maker Synthes, the EC says. Analysts speculate that JNJ may have to divest some trauma assets to win regulatory approval.
    | Comment!
  • Feb. 21, 2012, 4:43 PM
    Johnson & Johnson (JNJ) CEO Bill Weldon announces his retirement, following an embarrassing stretch of product recalls and speculation in winter 2010 that he would step down within the year. Alex Gorsky, head of medical devices and diagnostics, succeeds him.
    | 2 Comments
  • Feb. 21, 2012, 10:53 AM
    The Supreme Court rejects a request from Johnson & Johnson (JNJ -0.1%) to reinstate a $1.67B court ruling against Abbott Laboratories (ABT -0.4%) in a patent infringement case related to its Humira treatment for arthritis that contributes close to 20% of ABT's annual revenue.
    | Comment!
  • Feb. 17, 2012, 9:04 AM
    Johnson & Johnson (JNJ) is recalling about 574K bottles of its grape-flavored liquid infant Tylenol in the U.S. following complaints (but no adverse events) over the dosing system. It's the latest in a series of recalls involving Tylenol and other over-the-counter medications. (PR)
    | Comment!
Visit Seeking Alpha's
JNJ vs. ETF Alternatives
Company Description
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale ofproducts in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.